Recent Posts
- Experimental gene therapy ST-920 on FDA’s fast track
- Alpha-synuclein clumps contribute to Fabry kidney cell damage: Study
- Over half of adults with Fabry at risk of cardiac events: MRI study
- FDA OKs PRX-102, now Elfabrio, to treat adults with Fabry disease
- Fabry disease still underdiagnosed, especially among women: Study Â
- Patients favor enzyme replacement therapy done at home: Survey
- Centogene, Takeda to extend Fabry disease testing for one more year
- Freeline pauses development of Fabry disease gene therapy FLT190
- Celebrating ‘Fabry Heroes’ during Awareness Month this April
- Optimized versions of Gal A enzyme may pave way to better treatments